JPRN-jRCT2080221798UnknownPhase 3
A Long-Term Clinical Study of SFPP in Patients with Osteoarthritis
Conditions
Trial Snapshot
- Phase
- Phase 3
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •- Patients who require long-term NSAIDs treatment.
Exclusion Criteria
- •- Patients who are scheduled for surgery during the study period.
- •- Having critical hepatic disease, renal disease, heart disease and hematologic disease and malignant tumor.
Investigators
Similar Trials
Unknown
Unknown
A long term study of SPP100 in patients with essential hypertensioHypertensionJPRN-jRCT2080220180ovartis Pharma K.K.300
Unknown
Phase 3
Phase3 Study of SFPP in Patients with Osteoarthritis of the knee (Randomized, Parallel Group, Active Comparator-Controlled Study)Osteoarthritis of the kneeJPRN-jRCT2080221651Taisho Pharmaceutical co., LTD620
Active, not recruiting
Phase 1
A Long-term Follow-up Study of Patients with MPS IIIA from Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH)MPS IIIA is a devastating lysosomal storage disease, caused by a Nsulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progressive, with deterioration of social and adaptive abilities, neurocognitive decline, and premature death. Death typically occurs by end of the second or beginning of the third decade. Quite importantly, there is no treatmentcurrently available for the disease.MedDRA version: 20.1Level: PTClassification code 10056890Term: Mucopolysaccharidosis IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002979-34-ESAbeona Therapeutics Inc34
Active, not recruiting
Phase 1
A Long-term Follow-up Study of Patients with MPS IIIB from Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU)MPS IIIB is a devastating lysosomal storage disease, caused by a N-a-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progressive, with deterioration of social and adaptive abilities, neurocognitive decline, and premature death. Death typically occurs by end of the second or beginning of the third decade. Quite importantly, there is no treatment currently available for the disease.MedDRA version: 20.1Level: PTClassification code 10056890Term: Mucopolysaccharidosis IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002936-97-FRAbeona Therapeutics Europe SL.24
Active, not recruiting
Phase 1
A Long-term Follow-up Study of Patients with MPS IIIB from Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU)MPS IIIB is a devastating lysosomal storage disease, caused by a N-a-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progressive, with deterioration of social and adaptive abilities, neurocognitive decline, and premature death. Death typically occurs by end of the second or beginning of the third decade. Quite importantly, there is no treatment currently available for the disease.MedDRA version: 20.1Level: PTClassification code 10056890Term: Mucopolysaccharidosis IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-002936-97-DEAbeona Therapeutics Europe SL.24